Patent · US Active

Trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid

US8299060B2 · kind B2 · utility

0Cited by

8References

21Claims

0Family size

Assignee

ELI LILLY AND COMPANY · US

Inventors

Xinchao Chen · Schenectady, US
Scott Alan Frank · Indianapolis, US
Steven Wayne Pedersen · Indianapolis, US
David Michael Remick · Indianapolis, US

Key dates

Filing date	Jun 28, 2010
Grant date	Oct 30, 2012
Priority date	—
Expiry date	Jun 28, 2030

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P9/10
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Abstract Compounds of a formula entitled, trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid, as a free acid or a pharmaceutically acceptable salt thereof, hydrate, and hydrate in crystalline form; pharmaceutical formulations; and methods of use are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.